Hormone Axis Discussion
Sexual Wellness Research Discussion Protocol
Educational protocol for sexual health and wellness research compound discussions
• This protocol is provided for educational and informational purposes only. It does not constitute medical advice, a diagnosis, a treatment plan, or a prescription.
• All dose ranges, frequencies, durations, and compound selections must be determined by a licensed healthcare professional based on your individual medical history, lab results, and clinical assessment.
• Lab monitoring may be required depending on the compound(s), individual health status, and duration of use. Discuss appropriate monitoring protocols with your clinician.
• Do not use any peptide compound if you are pregnant, breastfeeding, a minor, or have uncontrolled medical conditions without explicit direction from your physician.
Overview
An educational protocol for sexual wellness discussions including FDA-approved and research-grade compounds. All discussions require sexual health or urology/gynecology specialist evaluation.
Mechanism Summary
Central melanocortin receptor agonism (PT-141) activates sexual arousal pathways centrally, distinct from peripheral vascular mechanisms. Oxytocin analogues are explored for bonding and intimacy facilitation in research contexts.
Intended Goal
Facilitate an informed clinician discussion about sexual wellness research options
PT-141 (Bremelanotide)
Melanocortin / sexual function
FDA-approved for premenopausal HSDD. Other uses require clinical evaluation.
Oxytocin peptide analogues
Social bonding / sexual wellness research
Oxytocin research in intimacy contexts. Catalog reference only.
Research reference values only. Confirm all parameters with current literature and your clinician.
Who may be a candidate
- ✓Adults with clinician-documented sexual health concerns
- ✓Individuals working with a sexual health specialist or urologist/gynecologist
Exclusions
- ✕Not for recreational use without clinical evaluation
- ✕Not appropriate for individuals with untreated cardiovascular conditions
Am I a candidate for PT-141 under its FDA-approved indication?
What hormonal factors may be contributing to my concerns?
Are there psychological components to address?
Print or copy these questions using the "Copy Summary" button to bring to your appointment.
Legal & Compliance Notice
PT-141/bremelanotide is FDA-approved for specific indications. Off-label use requires prescribing physician oversight.
The legal and regulatory status of research compounds varies by country and jurisdiction. It is the user's responsibility to understand applicable local laws before engaging with any compound.
This application does not provide personalized dosing recommendations. Users who require medical guidance should consult a qualified clinician.
Last reviewed: 2025-01-15 · Status: reviewed
Discuss with Your Clinician
Use this protocol as a research starting point. A qualified healthcare professional can review your health history, order appropriate labs, and help you determine what approach — if any — makes sense for your specific situation.